MicroRNAs and Metabolic Disorders - Where Are We Heading?

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2017 Jul 20

PMID 28721157

Citations 28

Authors

Agnieszka Sliwinska

Marta A Kasinska

Jozef Drzewoski

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs, miRs) are short, non-coding molecules engaged in normal functioning of eukaryotic cells, as negative regulators of gene expression. Since the first discovery of miRNA in the early 1990s, hundreds of different miRNAs and their targets have been identified. A growing number of studies have aimed to search for microRNAs which have a key role in the regulation of insulin signaling and metabolic homeostasis. Recent evidence indicates that dysregulation of miRNA expression is involved in the development of various diseases, including type 2 diabetes mellitus (T2DM), obesity and cardiovascular diseases. This review summarizes the biogenesis of miRNAs and their role in pancreatic β cell biology, insulin signaling and metabolism. We also discuss recent findings of miRNAs associated with metabolic disorders and vascular diabetic complications, their diagnosis and therapeutic value. The PubMed database and published reference lists were searched for articles published between 1990 and 2016 using the following keywords: miRNA, miRNA and pancreas; miRNA and insulin; miRNA and type 2 diabetes mellitus, miRNA and obesity, and miRNA and microvascular or macrovascular diabetic complication. This review indicates that miRNA functioning is significantly different in metabolic diseases than in the normal condition.

Citing Articles

Genetic and epigenetic alterations associated with gestational diabetes mellitus and adverse neonatal outcomes.

Shamsad A, Gautam T, Singh R, Banerjee M World J Clin Pediatr. 2025; 14(1):99231.

PMID: 40059904 PMC: 11686586. DOI: 10.5409/wjcp.v14.i1.99231.

The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials.

Liu Y, Han F, Xia Z, Sun P, Rohani P, Amirthalingam P Diabetol Metab Syndr. 2024; 16(1):93.

PMID: 38658994 PMC: 11044307. DOI: 10.1186/s13098-024-01319-7.

Placental microRNA methylome signatures may serve as biomarkers and therapeutic targets for prenatally opioid-exposed infants with neonatal opioid withdrawal syndrome.

Radhakrishna U, Nath S, Uppala L, Veerappa A, Forray A, Muvvala S Front Genet. 2023; 14:1215472.

PMID: 37434949 PMC: 10332887. DOI: 10.3389/fgene.2023.1215472.

Regulatory Roles of MicroRNAs in the Pathogenesis of Metabolic Syndrome.

Rahman M, Islam M, Ripon M, Islam M, Hossain M Mol Biotechnol. 2023; 66(7):1599-1620.

PMID: 37393414 DOI: 10.1007/s12033-023-00805-z.

Dietary Impacts on Gestational Diabetes: Connection between Gut Microbiome and Epigenetic Mechanisms.

Bankole T, Winn H, Li Y Nutrients. 2022; 14(24).

PMID: 36558427 PMC: 9786016. DOI: 10.3390/nu14245269.

References

Raz I, Eldor R, Cernea S, Shafrir E . Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev. 2004; 21(1):3-14. DOI: 10.1002/dmrr.493. View

Gagan J, Dey B, Layer R, Yan Z, Dutta A . MicroRNA-378 targets the myogenic repressor MyoR during myoblast differentiation. J Biol Chem. 2011; 286(22):19431-8. PMC: 3103322. DOI: 10.1074/jbc.M111.219006. View

Finlay D, Rosenzweig E, Sinclair L, Feijoo-Carnero C, Hukelmann J, Rolf J . PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012; 209(13):2441-53. PMC: 3526360. DOI: 10.1084/jem.20112607. View

Karolina D, Tavintharan S, Armugam A, Sepramaniam S, Pek S, Wong M . Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012; 97(12):E2271-6. DOI: 10.1210/jc.2012-1996. View

McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S . MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011; 60(4):1314-23. PMC: 3064105. DOI: 10.2337/db10-1557. View

Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

Herrera B, Lockstone H, Taylor J, Ria M, Barrett A, Collins S . Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia. 2010; 53(6):1099-109. PMC: 2860560. DOI: 10.1007/s00125-010-1667-2. View

Karolina D, Armugam A, Tavintharan S, Wong M, Lim S, Sum C . MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011; 6(8):e22839. PMC: 3148231. DOI: 10.1371/journal.pone.0022839. View

Bork-Jensen J, Scheele C, Christophersen D, Nilsson E, Friedrichsen M, Fernandez-Twinn D . Glucose tolerance is associated with differential expression of microRNAs in skeletal muscle: results from studies of twins with and without type 2 diabetes. Diabetologia. 2014; 58(2):363-73. PMC: 4287682. DOI: 10.1007/s00125-014-3434-2. View

10.

Siomi H, Siomi M . Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010; 38(3):323-32. DOI: 10.1016/j.molcel.2010.03.013. View

11.

Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-76. DOI: 10.1038/35096075. View

12.

Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M . Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A. 2004; 101(27):10042-7. PMC: 454161. DOI: 10.1073/pnas.0400593101. View

13.

Yousefzadeh N, Alipour M, Ghadiri Soufi F . Deregulation of NF-кB-miR-146a negative feedback loop may be involved in the pathogenesis of diabetic neuropathy. J Physiol Biochem. 2015; 71(1):51-8. DOI: 10.1007/s13105-014-0378-4. View

14.

Alvarez M, Khosroheidari M, Eddy E, Done S . MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015; 242(2):595-604. PMC: 4575910. DOI: 10.1016/j.atherosclerosis.2015.08.023. View

15.

Rayner K, Suarez Y, Davalos A, Parathath S, Fitzgerald M, Tamehiro N . MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010; 328(5985):1570-3. PMC: 3114628. DOI: 10.1126/science.1189862. View

16.

Zhao J, Chen P, Duan R, Li K, Wang Y, Li Y . miR-630 functions as a tumor oncogene in renal cell carcinoma. Arch Med Sci. 2016; 12(3):473-8. PMC: 4889681. DOI: 10.5114/aoms.2016.59918. View

17.

Herrera B, Lockstone H, Taylor J, Wills Q, Kaisaki P, Barrett A . MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of Type 2 Diabetes. BMC Med Genomics. 2009; 2:54. PMC: 2754496. DOI: 10.1186/1755-8794-2-54. View

18.

Wu W, Yan H, Wang X, Gui Y, Gao F, Tang X . Sodium tanshinone IIA silate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration through activation of AMP-activated protein kinase. PLoS One. 2014; 9(4):e94957. PMC: 3989257. DOI: 10.1371/journal.pone.0094957. View

19.

Baldeon R L, Weigelt K, de Wit H, Ozcan B, van Oudenaren A, Sempertegui F . Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients. PLoS One. 2014; 9(12):e115209. PMC: 4264887. DOI: 10.1371/journal.pone.0115209. View

20.

Kamagate A, Qu S, Perdomo G, Su D, Kim D, Slusher S . FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest. 2008; 118(6):2347-64. PMC: 2391277. DOI: 10.1172/JCI32914. View